,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['mbc', 'breast', 'destiny-breast04']
the results of destiny-breast04 live from #asco22 did you hear? the phase 3 trial of a her2-directed therapy is the first to show a statistically significant and clinically meaningful benefit in pfs and os vs tpc. an exciting new treatment for her2-low mbc on the horizon! 